Drug AMG 410 for metastatic tumors with KRAS mutations (20240031) - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
[20240031] A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
Principal Investigator
John H. Strickler, MD
Medical Oncologist
Protocol Number
IRB:
PRO00118236
NCT:
NCT07094113
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu